Bank of New York Mellon’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $210K | Sell |
161,689
-141,739
| -47% | -$225K | ﹤0.01% | 4126 |
|
|
2026
Q1 | $492K | Sell |
303,428
-25,567
| -8% | -$52.5K | ﹤0.01% | 3616 |
|
|
2025
Q4 | $924K | Sell |
328,995
-18,490
| -5% | -$42.9K | ﹤0.01% | 3288 |
|
|
2025
Q3 | $716K | Buy |
347,485
+13,528
| +4% | +$37.4K | ﹤0.01% | 3397 |
|
|
2025
Q2 | $1.05M | Buy |
333,957
+10,610
| +3% | +$32.4K | ﹤0.01% | 3101 |
|
|
2025
Q1 | $1.02M | Buy |
323,347
+34,732
| +12% | +$137K | ﹤0.01% | 3062 |
|
|
2024
Q4 | $1.25M | Buy |
288,615
+117,514
| +69% | +$367K | ﹤0.01% | 3013 |
|
|
2024
Q3 | $457K | Buy |
171,101
+55,797
| +48% | +$132K | ﹤0.01% | 3570 |
|
|
2024
Q2 | $256K | Buy |
+115,304
| New | +$435K | ﹤0.01% | 3876 |
|
|
2024
Q1 | – | Sell |
-14,350
| Closed | -$21.2K | – | 4191 |
|
|
2023
Q4 | $21.2K | Hold |
14,350
| – | – | ﹤0.01% | 4231 |
|
|
2023
Q3 | $19.9K | Hold |
14,350
| – | – | ﹤0.01% | 4253 |
|
|
2023
Q2 | $21.1K | Hold |
14,350
| – | – | ﹤0.01% | 4281 |
|
|
2023
Q1 | $23.7K | Hold |
14,350
| – | – | ﹤0.01% | 4291 |
|
|
2022
Q4 | $20.1K | Hold |
14,350
| – | – | ﹤0.01% | 4357 |
|
|
2022
Q3 | $22K | Sell |
14,350
-135
| -0.9% | -$325 | ﹤0.01% | 4441 |
|
|
2022
Q2 | $32K | Sell |
14,485
-100,906
| -87% | -$169K | ﹤0.01% | 4438 |
|
|
2022
Q1 | $286K | Sell |
115,391
-4,985
| -4% | -$17.6K | ﹤0.01% | 4037 |
|
|
2021
Q4 | $723K | Buy |
120,376
+8,320
| +7% | +$49.6K | ﹤0.01% | 3571 |
|
|
2021
Q3 | $746K | Buy |
112,056
+7,848
| +8% | +$49.3K | ﹤0.01% | 3571 |
|
|
2021
Q2 | $693K | Buy |
104,208
+89,859
| +626% | +$762K | ﹤0.01% | 3616 |
|
|
2021
Q1 | $133K | Sell |
14,349
-1,467
| -9% | -$17.8K | ﹤0.01% | 4127 |
|
|
2020
Q4 | $285K | Sell |
15,816
-46,608
| -75% | -$819K | ﹤0.01% | 3848 |
|
|
2020
Q3 | $886K | Buy |
+62,424
| New | +$412K | ﹤0.01% | 3197 |
|
|
2018
Q2 | – | Sell |
-444
| Closed | -$11K | – | 4222 |
|
|
2018
Q1 | $11K | Sell |
444
-341
| -43% | -$8.41K | ﹤0.01% | 4290 |
|
|
2017
Q4 | $17K | Buy |
785
+29
| +4% | +$1.28K | ﹤0.01% | 4310 |
|
|
2017
Q3 | $39K | Buy |
756
+389
| +106% | +$24.3K | ﹤0.01% | 4144 |
|
|
2017
Q2 | $33K | Sell |
367
-909
| -71% | -$58.5K | ﹤0.01% | 4182 |
|
|
2017
Q1 | $106K | Sell |
1,276
-8
| -0.6% | -$1.09K | ﹤0.01% | 4017 |
|
|
2016
Q4 | $194K | Sell |
1,284
-238
| -16% | -$55.6K | ﹤0.01% | 3913 |
|
|
2016
Q3 | $492K | Sell |
1,522
-64
| -4% | -$23.3K | ﹤0.01% | 3545 |
|
|
2016
Q2 | $518K | Sell |
1,586
-2
| -0.1% | -$689 | ﹤0.01% | 3520 |
|
|
2016
Q1 | $532K | Buy |
1,588
+295
| +23% | +$100K | ﹤0.01% | 3413 |
|
|
2015
Q4 | $503K | Hold |
1,293
| – | – | ﹤0.01% | 3524 |
|
|
2015
Q3 | $529K | Sell |
1,293
-125
| -9% | -$65.4K | ﹤0.01% | 3561 |
|
|
2015
Q2 | $1.04M | Buy |
1,418
+1,169
| +469% | +$829K | ﹤0.01% | 3315 |
|
|
2015
Q1 | $122K | Hold |
249
| – | – | ﹤0.01% | 4002 |
|
|
2014
Q4 | $77K | Hold |
249
| – | – | ﹤0.01% | 4099 |
|
|
2014
Q3 | $82K | Hold |
249
| – | – | ﹤0.01% | 4089 |
|
|
2014
Q2 | $63K | Buy |
249
+4
| +2% | +$1.28K | ﹤0.01% | 4051 |
|
|
2014
Q1 | $101K | Hold |
245
| – | – | ﹤0.01% | 3984 |
|
|
2013
Q4 | $101K | Hold |
245
| – | – | ﹤0.01% | 4014 |
|
|
2013
Q3 | $127K | Buy |
245
+71
| +41% | +$40.4K | ﹤0.01% | 3903 |
|
|
2013
Q2 | $88K | Buy |
+174
| New | +$78.6K | ﹤0.01% | 3953 |
|
Other funds holding CRDF
FLPIM
GCP
AC
AC
CWP
QC
Bank of New York Mellon's CRDF Position: Q2 2026 in Review
Bank of New York Mellon reduced its Cardiff Oncology (CRDF) stake by 47% in Q2 2026, selling an estimated $225K and leaving 161,689 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #4126.
Bank of New York Mellon first reported a position in CRDF in Q2 2013 and has held it in 43 quarters since. The position peaked at $1.25M in Q4 2024. 40 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.
- Bank of New York Mellon held 161,689 shares of Cardiff Oncology worth $210K as of Q2 2026.
- Bank of New York Mellon sold 141,739 Cardiff Oncology shares in Q2 2026, an estimated $225K.
- Cardiff Oncology made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4126 holding.
- Bank of New York Mellon first reported a position in Cardiff Oncology in Q2 2013 and has held it in 43 quarters since.
- Bank of New York Mellon's Cardiff Oncology position peaked at $1.25M in Q4 2024.
- 40 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.